With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1194-16-7,2,2-Dimethyltetrahydropyran-4-one,as a common compound, the synthetic route is as follows.
To a solution of benzyloxycarbonyl-a-phosphonoglycine trimethyl ester (1.163 g, 3.52 mmol) in dry DCM (20 mL) was added DBU (0.534 g, 3.52 mmol) dropwise at 0C. Then a solution of compound cap 3a (1.8 g, 14.08 mmol) in dry DCM (20 mL) was added dropwise at 0C. The reaction mixture was stirred at 25C for 3 days. After removal of the solvent, the residue was purified using Si02 chromatography (e luting with petroleum ether/ ethyl acetate = 5: 1 to 3: 1) to providecompound cap 3b as white solid (0.15 g, 13% yield). 1H NMR (CDC13): delta 7.30-7.35 (m, 5 H), 5.11 (s, 2 H), 3.82-3.88 (m, 3 H), 3.09-3.16 (m, 2 H), 1.84 (s, 2 H), 1.48 (s, 2 H), 1194-16-7
As the paragraph descriping shows that 1194-16-7 is playing an increasingly important role.
Reference£º
Patent; MERCK SHARP & DOHME CORP.; YU, Wensheng; TONG, Ling; KOZLOWSKI, Joseph A.; SELYUTIN, Oleg; CHEN, Lei; KIM, Jae-Hun; SHA, Deyou; RIZVI, Razia; SHANKAR, Bandarpalle; HU, Bin; ZHONG, Bin; WAI, Dahai; HAO, Jinglai; WEI, Wei; JI, Tao; ZAN, Shuai; WO2014/110705; (2014); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics